Positive results from RXi NeuVax Phase 2 trial on breast cancer presented at ASCO 201
 

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using targeted biotherapeutics, announced updated data from its Phase 2 clinical trial of NeuVax at the American Society of Clinical Oncology (ASCO) annual meeting.

More...